These results correlated with previously published observations, demonstrating a progression of the Nr2e1-null phenotype during neocortex development, with a greater effect between E13 and E15 [ 9].
Roldan et al 3 demonstrated a progression of CKD ≥10 mL/min in 21% of patients with AF at 2 years of follow-up, with age, female gender and arterial hypertension being significantly associated with a decline in renal function.
The types of post-resection/TACE treatments for the two groups were not significantly different (Table 3).> A total of 11 patients in the resection group demonstrated a progression of the disease after partial hepatectomy, while 2 of the 4 patients without progression survived 168.1 and 13.0 months, respectively; the other 2 patients were censored because of lost follow-up.
This hypothesis is consistent with our results, which through serial electrophysiological testing demonstrated a progression of HV interval in only five of 25 patients during a prolonged period of 90 months as opposed to Prystowsky et al, 14 who reported an aggravation of HV interval in seven of nine selected patients during a short 3-year period.
42– 46 Although a meta-analysis of published randomized trials demonstrated a progression-free survival benefit (HR: 0.78, 95% CI 0.70 0.86), there was no overall survival benefit.
Three patients were re-challenged with capecitabine/MMC and seven with capecitabine alone; these patients demonstrated a progression-free interval of ⩾6 months after an initial response to XMMC.
Gefitinib and erlotinib are reversible first-generation inhibitors of mutant EGFR, and treatment with these agents in the first-line setting has demonstrated a progression-free survival of 9.5 13.7 months.
Anti-tumor activity of everolimus 10 mg daily was shown in a phase 2 trial of patients with mRCC [ 22, 23], and results of the phase 3 RECORD-1 study demonstrated a progression-free survival (PFS) benefit of everolimus 10 mg daily over placebo in patients with VEGFr-TKI refractory mRCC (4.9 VEGFr-TKI refractory33; 95% CI, 0.25-0.43; P <.001) [ 10].
We demonstrate a rapid progression of diaphragm atrophy, with already a significant decrease in thickness after just 1 day of MV, and the largest decrease in diaphragm thickness occurring during the first 72 hours of MV.
Disruptions of surgical flow have been associated with increased rates of surgical error [ 20], so it is important that trainees demonstrate a smooth progression through the steps of the operation.
